As Dr. J and DP and others have commented, its actually interesting and a bit surprising to see Leronlimab efficacious in the mild to moderate. Does any one know if viral load is included in the CD10 measurements? Seeing viral load drop faster in this cohort would be encouraging. This would help make the case that its not just inflammation response and be powerful data for any FDA decisions, imo.